(Q38062792)

28 August 2017

1 reference

title

Clinical opportunities and challenges in targeting tumour dormancy (English)

1 reference

28 August 2017

Jonathan A Hensel

1

1 reference

28 August 2017

Thomas W Flaig

series ordinal

2

1 reference

28 August 2017

Dan Theodorescu

series ordinal

3

1 reference

28 August 2017

language of work or name

English

0 references

publication date

27 November 2012

1 reference

Nature Reviews Clinical Oncology

28 August 2017

published in

1 reference

28 August 2017

volume

10

1 reference

28 August 2017

issue

1

1 reference

28 August 2017

page(s)

41-51

1 reference

https://scigraph.springernature.com/pub.10.1038/nrclinonc.2012.207

28 August 2017

exact match

0 references

cites work

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.207

The distribution of secondary growths in cancer of the breast. 1889

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.207

Tumor angiogenesis: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.207

Tumor dormancy and immunoescape.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.207

Models, mechanisms and clinical evidence for cancer dormancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.207

Detection, clinical relevance and specific biological properties of disseminating tumour cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.207

Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and limited survival of early micrometastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.207

Gap junction-mediated import of microRNA from bone marrow stromal cells can elicit cell cycle quiescence in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.207

Uncertainty in the niches that maintain haematopoietic stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.207

VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging α4β1-positive osteoclast progenitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.207

Autophagy, senescence and tumor dormancy in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.207

Survivin and escaping in therapy-induced cellular senescence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.207

Bone morphogenetic protein 7 in dormancy and metastasis of prostate cancer stem-like cells in bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.207

Development of novel therapeutics targeting the urokinase plasminogen activator receptor (uPAR) and their translation toward the clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.207

Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.207

Green fluorescent protein tagging of extracellular signal-regulated kinase and p38 pathways reveals novel dynamics of pathway activation during primary and metastatic growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.207

Urokinase receptor and fibronectin regulate the ERK(MAPK) to p38(MAPK) activity ratios that determine carcinoma cell proliferation or dormancy in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.207

Reduction in surface urokinase receptor forces malignant cells into a protracted state of dormancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.207

Reciprocal interactions between beta1-integrin and epidermal growth factor receptor in three-dimensional basement membrane breast cultures: a different perspective in epithelial biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.207

Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.207

Integrin alpha(v)beta(3)/vitronectin interaction affects expression of the urokinase system in human ovarian cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.207

The p38 kinases MKK4 and MKK6 suppress metastatic colonization in human ovarian carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.207

c-Jun NH2-terminal kinase activating kinase 1/mitogen-activated protein kinase kinase 4-mediated inhibition of SKOV3ip.1 ovarian cancer metastasis involves growth arrest and p21 up-regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.207

Probing prokaryotic social behaviors with bacterial "lobster traps"

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.207

Disruption of a Quorum Sensing mechanism triggers tumorigenesis: a simple discrete model corroborated by experiments in mammary cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.207

Societal interactions in ovarian cancer metastasis: a quorum-sensing hypothesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.207

Inhibition of metastatic outgrowth from single dormant tumor cells by targeting the cytoskeleton.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.207

Metastasis: a therapeutic target for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.207

Noninvasive measurement of microvascular and interstitial oxygen profiles in a human tumor in SCID mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.207

Role of angiogenesis in human tumor dormancy: animal models of the angiogenic switch

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.207

Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.207

Hematopoietic cells regulate the angiogenic switch during tumorigenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.207

Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.207

Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.207

The role of tumor hypoxia in MUC1-positive breast carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.207

FGF-1 but not FGF-4 secreted by carcinoma cells promotes in vitro and in vivo angiogenesis and rapid tumor proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.207

Cancer and the chemokine network

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.207

Extrinsic regulators of epithelial tumor progression: metalloproteinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.207

Angiogenesis: vascular remodeling of the extracellular matrix involves metalloproteinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.207

Induction of angiogenesis during the transition from hyperplasia to neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.207

Targeting HIF-1 for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.207

A model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.207

Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.207

Interruption of tumor dormancy by a transient angiogenic burst within the tumor microenvironment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.207

Suppression of heat shock protein 27 induces long-term dormancy in human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.207

Transcriptional switch of dormant tumors to fast-growing angiogenic phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.207

The three Es of cancer immunoediting

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.207

B7-H1 up-regulation on dendritic-like leukemia cells suppresses T cell immune function through modulation of IL-10/IL-12 production and generation of Treg cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.207

Immune-mediated dormancy: an equilibrium with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.207

Adenosine A2B receptor blockade slows growth of bladder and breast tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.207

Transmission of donor melanoma by organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.207

Controversies in clinical cancer dormancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.207

Regulatory T cells, tumour immunity and immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.207

Immune cells and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.207

Tumour macrophages as potential targets of bisphosphonates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.207

Tumor endothelin-1 enhances metastatic colonization of the lung in mouse xenograft models of bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.207

RhoGDI2 is an invasion and metastasis suppressor gene in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.207

RhoGDI2 suppresses lung metastasis in mice by reducing tumor versican expression and macrophage infiltration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.207

Metastasis Suppressor Genes: Basic Biology and Potential Clinical Use

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.207

Requirement of KISS1 secretion for multiple organ metastasis suppression and maintenance of tumor dormancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.207

The role of metastasis suppressor genes in metastatic dormancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.207

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.207

Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.207

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.207

Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.207

Residual dormant cancer stem-cell foci are responsible for tumor relapse after antiangiogenic metronomic therapy in hepatocellular carcinoma xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.207

A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.207

Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.207

Immunostimulatory effects of low-dose cyclophosphamide are controlled by inducible nitric oxide synthase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.207

Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.207

Metronomic cyclophosphamide in elderly patients with advanced, castration-resistant prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.207

Metronomic chemotherapy: new rationale for new directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.207

Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.207

Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.207

A 20-gene model for molecular nodal staging of bladder cancer: development and prospective assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.207

Computed Tomography — An Increasing Source of Radiation Exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.207

Detection and characterization of carcinoma cells in the blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.207

Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.207

Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.207

Genomic analysis of circulating cell-free DNA infers breast cancer dormancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.207

Circulating microRNAs as stable blood-based markers for cancer detection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.207

Increased MKK4 abundance with replicative senescence is linked to the joint reduction of multiple microRNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.207

In vivo MRI of cancer cell fate at the single-cell level in a mouse model of breast cancer metastasis to the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.207

Clinical Significance and Molecular Characteristics of Circulating Tumor Cells and Circulating Tumor Microemboli in Patients With Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.207

Evidence for the clonal origin of spontaneous metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.207

31 March 2020

The dormant cancer cell

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.207

Local Recurrences Following Mastectomy: Support for the Concept of Tumor Dormancy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.207

Time distribution of the recurrence risk for breast cancer patients undergoing mastectomy: Further support about the concept of tumor dormancy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.207

Transplacental carcinogenesis by stilbestrol

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.207

Circulating tumor cells in breast cancer: correlation to bone marrow micrometastases, heterogeneous response to systemic therapy and low proliferative activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.207

Breast cancer cell dormancy in bone marrow: potential therapeutic targets within the marrow microenvironment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.207

Circulating tumor cells in patients with breast cancer dormancy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.207

Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.207

Matrix metalloproteinases and angiogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.207

Phase 2 study of ABT-510 in patients with previously untreated advanced renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.207

Transplant tumor registry: donor related malignancies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.207

Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.207

Placebo-associated remissions in a multicentre, randomized, double-blind trial of interferon gamma-1b for the treatment of metastatic renal cell carcinoma. The Canadian Urologic Oncology Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.207

The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.207

Three-Dimensional Imaging and Quantification of Both Solitary Cells and Metastases in Whole Mouse Liver by Magnetic Resonance Imaging

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.207

A Gompertzian model of human breast cancer growth.

31 March 2020

1 reference

12 December 2020

Tumor-vascular interactions and tumor dormancy

1 reference

12 December 2020

A primary tumor promotes dormancy of solitary tumor cells before inhibiting angiogenesis.

1 reference

12 December 2020

ERK(MAPK) activity as a determinant of tumor growth and dormancy; regulation by p38(SAPK).

1 reference

12 December 2020

Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs.

1 reference

12 December 2020

Molecular assays for the diagnosis of minimal residual head-and-neck cancer: methods, reliability, pitfalls, and solutions

1 reference

12 December 2020

Systemic therapy in renal cell carcinoma: advancing paradigms

1 reference

12 December 2020

Effect of surgical removal on the growth and kinetics of residual tumor

1 reference

12 December 2020

Temporal progression of metastasis in lung: cell survival, dormancy, and location dependence of metastatic inefficiency

1 reference

12 December 2020

10.1038/NRCLINONC.2012.207

Identifiers

DOI

1 reference

Dimensions Publication ID

28 August 2017

1015861176

0 references

1 reference